Free Trial
NASDAQ:ATOS

Atossa Genetics Q1 2025 Earnings Report

Atossa Genetics logo
$0.83 +0.03 (+3.29%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$0.82 -0.01 (-0.85%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atossa Genetics EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Atossa Genetics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atossa Genetics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Atossa Genetics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Atossa Genetics Earnings Headlines

Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
See More Atossa Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atossa Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atossa Genetics and other key companies, straight to your email.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics (NASDAQ:ATOS) and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

View Atossa Genetics Profile

More Earnings Resources from MarketBeat